mTOR抑制剂的疗效由eIF4E/4E-BP比率决定。 - Suppr

Suppr

超能文献

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio.

作者信息

Alain Tommy, Sonenberg Nahum, Topisirovic Ivan

出版信息

Oncotarget. 2012 Dec;3(12):1491-2. doi: 10.18632/oncotarget.799.

DOI:10.18632/oncotarget.799

PMID:23455427

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3681483/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0099/3681483/acea2fd6ec14/oncotarget-03-1491-g001.jpg

相似文献

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio.

Oncotarget. 2012 Dec;3(12):1491-2. doi: 10.18632/oncotarget.799.

eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.

Cancer Res. 2012 Dec 15;72(24):6468-76. doi: 10.1158/0008-5472.CAN-12-2395. Epub 2012 Oct 24.

Inhibitors of mTOR in aging and cancer.

Oncotarget. 2015 Dec 29;6(42):45010-1. doi: 10.18632/oncotarget.6878.

CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.

Oncotarget. 2016 May 10;7(19):27787-801. doi: 10.18632/oncotarget.8497.

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

PLoS Pathog. 2018 Aug 23;14(8):e1007264. doi: 10.1371/journal.ppat.1007264. eCollection 2018 Aug.

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.

Mol Cell Biol. 2007 Nov;27(21):7405-13. doi: 10.1128/MCB.00760-07. Epub 2007 Aug 27.

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.

BMC Cancer. 2021 Sep 26;21(1):1061. doi: 10.1186/s12885-021-08782-9.

[mTOR inhibitor].

Gan To Kagaku Ryoho. 2011 Jan;38(1):7-11.

Clinical significance of mTOR and eIF4E expression in invasive ductal carcinoma.

Tumori. 2014 Sep-Oct;100(5):541-6. doi: 10.1700/1660.18176.

Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e395.

引用本文的文献

TRIBE editing reveals specific mRNA targets of eIF4E-BP in and in mammals.

Sci Adv. 2020 Aug 12;6(33):eabb8771. doi: 10.1126/sciadv.abb8771. eCollection 2020 Aug.

Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia.

J Mol Endocrinol. 2019 Feb 1;62(2):R83-R103. doi: 10.1530/JME-18-0058.

The eIF4E2-Directed Hypoxic Cap-Dependent Translation Machinery Reveals Novel Therapeutic Potential for Cancer Treatment.

Oxid Med Cell Longev. 2017;2017:6098107. doi: 10.1155/2017/6098107. Epub 2017 Nov 26.

mTORC1 signalling and eIF4E/4E-BP1 translation initiation factor stoichiometry influence recombinant protein productivity from GS-CHOK1 cells.

Biochem J. 2016 Dec 15;473(24):4651-4664. doi: 10.1042/BCJ20160845. Epub 2016 Oct 19.

Catenin delta-1 (CTNND1) phosphorylation controls the mesenchymal to epithelial transition in astrocytic tumors.

Hum Mol Genet. 2016 Oct 1;25(19):4201-4210. doi: 10.1093/hmg/ddw253. Epub 2016 Aug 11.

mTOR signaling: new networks for ALL.

Blood. 2016 Jun 2;127(22):2658-9. doi: 10.1182/blood-2016-03-703199.

Adaptations to chronic rapamycin in mice.

Pathobiol Aging Age Relat Dis. 2016 May 27;6:31688. doi: 10.3402/pba.v6.31688. eCollection 2016.

Targeting mTOR for the treatment of B cell malignancies.

Br J Clin Pharmacol. 2016 Nov;82(5):1213-1228. doi: 10.1111/bcp.12888. Epub 2016 Mar 3.

Signalling to eIF4E in cancer.

Biochem Soc Trans. 2015 Oct;43(5):763-72. doi: 10.1042/BST20150126.

Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis.

Int J Clin Exp Pathol. 2015 Jan 1;8(1):404-13. eCollection 2015.

本文引用的文献

eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies.

Cancer Res. 2012 Dec 15;72(24):6468-76. doi: 10.1158/0008-5472.CAN-12-2395. Epub 2012 Oct 24.

Emerging therapeutics targeting mRNA translation.

Cold Spring Harb Perspect Biol. 2012 Apr 1;4(4):a012377. doi: 10.1101/cshperspect.a012377.

Rapamycin passes the torch: a new generation of mTOR inhibitors.

Nat Rev Drug Discov. 2011 Oct 31;10(11):868-80. doi: 10.1038/nrd3531.

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E699-708. doi: 10.1073/pnas.1108237108. Epub 2011 Aug 29.

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation.

Trends Biochem Sci. 2011 Jun;36(6):320-8. doi: 10.1016/j.tibs.2011.03.006. Epub 2011 Apr 30.

Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer.

Mol Cancer. 2011 Feb 14;10:19. doi: 10.1186/1476-4598-10-19.

mTOR: from growth signal integration to cancer, diabetes and ageing.

Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35. doi: 10.1038/nrm3025. Epub 2010 Dec 15.

4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications.

Cancer Res. 2007 Aug 15;67(16):7551-5. doi: 10.1158/0008-5472.CAN-07-0881.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验